Home -> Law Blog Directory -> Intellectual Property Law Blogs -> IP Blawg
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Intellectual Property Law
: IP BlawgFTC v. Schering-Plough: DOJ Opposes Cert
By Farella Braun + Martel LLP
We told you back in January about the possible involvement of the Supreme Court in the question of whether Schering-Plough?s authorized generics agreement violates unfair competition laws. The Supreme Court took the somewhat unusual step of asking the Solicitor General?s office to weigh in on the Federal Trade Commission?s antitrust case against Schering-Plough, which argued that patent infringement settlements should not be automatically shielded from antitrust review where the allegedly infringing product is precluded from entering the market prior to expiration of the patent. The 11th Circuit disagreed, and in considering the petition for certiorari, the Supreme Court sought the government?s opinion, even though the FTC was already in the case. The government?s brief has now been filed, and perhaps not surprisingly, the Department of Justice takes a different view as to the enforcement of the antitrust laws.
In the view of the United States, the [FTC's] petition for a writ of certiorari should be denied. The decision below does not conflict with any decisions of this Court or the courts of appeals, and the only important but unsettled issues of federal law that are raised by the petition are not well presented in this case.
Will the Supreme Court end up taking the case? The Solicitor General?s opinion is not dispositive, so stay tuned.
Today's Blogger: Nan Joesten
Full post as published by IP Blawg on May 19, 2006 (boomark / email).
Schering Plough, Merck
Settle Multi-State Investigation for $5.4 Million
Perdidas Por Planes de Ahorro de Empleados de Schering
Merck, Schering
Settle Vytorin Zetia Class Action

Timeline: How Vytorin Fell Short
Drug Makers Release Test Results That Shows That Their Cholesterol Drug Zetia Has No Benefits
Bad News for Vytorin: "It just doesn't work"
Merck and Schering-Plough Defend Vytorin and Zetia
Damages: $0 settlement; Attorneys' fees: $9.5 million








